Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
On April 30, 2026, the FDA moved further - formally proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely, citing no clinical need for large-scale outsourcing facilities to compound these drugs from bulk substances
This non-selectivity explains the compound's multiple effects: tanning through MC1R activation produces skin darkening without UV exposure
If you have access to these accounts, using them for tirzepatide is one of the most impactful savings strategies available
Prescription-based fulfillment If prescribed, fulfillment depends on the medication, state, and dispensing-pharmacy pathway
Were also defining the market too narrowly
